Jaguar Health, Inc. 8-K

What Happened

• Jaguar Health, Inc. (through its wholly‑owned subsidiary Napo Pharmaceuticals, Inc.) filed an 8‑K on July 14, 2026 to announce a new manufacturing and supply agreement with Alivus Life Sciences Limited dated July 9, 2026.
• Under the agreement Alivus will continue to manufacture crofelemer for Mytesi® and other crofelemer‑based products. The term runs through March 31, 2029, with the possibility of successive renewals by mutual agreement.

Key Details

• Agreement date: July 9, 2026; term expires March 31, 2029 (renewable for minimum two‑year terms by mutual consent).
• Minimum purchase commitment: Napo must buy specified minimum quantities of crofelemer (pro‑rated for the fiscal year during the term); Napo/Company may owe payments for any shortfall. Quarterly quantity caps apply unless capacity is expanded at Napo’s written request.
• Termination rights: either party may end the agreement for any reason with 12 months’ notice; material breaches may be terminated after a 90‑day cure period; immediate termination allowed for bankruptcy/insolvency events. Napo may terminate immediately if regulatory authorities withdraw crofelemer/CPL for safety/non‑compliance or after 30 days for chronic supply failures.
• Related assignment: per a separate January 12, 2026 license agreement, Napo’s rights/obligations under this manufacturing agreement would be assigned to Woodward Specialty LLC if an “Insolvency Event” occurs.
• The manufacturing agreement is filed as Exhibit 10.1 to the 8‑K (certain confidential, non‑material information redacted).

Why It Matters

• This agreement secures a manufacturer for crofelemer—Jaguar’s active ingredient for Mytesi®—through 2029, providing supply continuity for its marketed product and other crofelemer programs.
• The minimum purchase and shortfall payment terms create a contractual demand obligation that could affect cash flow or inventory planning if sales volumes change.
• Termination and assignment provisions (including the potential assignment to Woodward on insolvency) are important for assessing supply risk and what happens if Jaguar/Napo faces financial distress.